scholarly journals Differential Effects of Denileukin Diftitox IL-2 Immunotoxin on NK and Regulatory T Cells in Nonhuman Primates

2012 ◽  
Vol 188 (12) ◽  
pp. 6063-6070 ◽  
Author(s):  
Yohei Yamada ◽  
Akihiro Aoyama ◽  
Georges Tocco ◽  
Svjetlan Boskovic ◽  
Ognjenka Nadazdin ◽  
...  
Gut ◽  
2015 ◽  
Vol 65 (10) ◽  
pp. 1642-1664 ◽  
Author(s):  
Anika Fischer ◽  
Sebastian Zundler ◽  
Raja Atreya ◽  
Timo Rath ◽  
Caroline Voskens ◽  
...  

Blood ◽  
2002 ◽  
Vol 100 (9) ◽  
pp. 3408-3414 ◽  
Author(s):  
Kevin J. Young ◽  
Liming Yang ◽  
M. James Phillips ◽  
Li Zhang

Abstract Donor-lymphocyte infusion (DLI) before transplantation can lead to specific tolerance to allografts in mice, nonhuman primates, and humans. We and others have demonstrated a role for regulatory T cells in DLI-induced, donor-specific transplantation tolerance, but it is not known how regulatory T cells are activated and where they execute their function. In this study, we observed, in both transgenic and normal mice, that DLI before transplantation is required for activation of αβ-T-cell-receptor–positive, CD3+CD4−CD8− double-negative (DN) regulatory T cells in the periphery of recipient mice. More interestingly, DLI induced DN regulatory T cells to migrate preferentially to donor-specific allogeneic skin grafts and to form a majority of graft-infiltrating T cells in accepted skin allografts. Furthermore, both recipient-derived peripheral and graft-infiltrating DN T cells were able to suppress and kill antidonor CD8+ T cells in an antigen-specific manner. These data indicate that DLI may induce donor-specific transplantation tolerance by activating recipient DN regulatory T cells in the periphery and by promoting migration of regulatory T cells to donor-specific allogeneic skin grafts. Our results also show that DN regulatory T cells can eliminate antidonor T cells both systemically and locally, a finding suggesting that graft-infiltrating T cells can be beneficial to graft survival.


2016 ◽  
Vol 168 ◽  
pp. 47-54 ◽  
Author(s):  
Charlotte M. Huijts ◽  
Saskia J. Santegoets ◽  
Maria Quiles del Rey ◽  
Richard R. de Haas ◽  
Henk M. Verheul ◽  
...  

2006 ◽  
Vol 119 ◽  
pp. S60
Author(s):  
Sebastiaan Vastert ◽  
Astrid Van der Meer ◽  
Isme De Kleer ◽  
Mark Klein ◽  
Wietse Kuis ◽  
...  

2007 ◽  
Vol 37 (7) ◽  
pp. 1809-1816 ◽  
Author(s):  
Clemens Neufert ◽  
Christoph Becker ◽  
Stefan Wirtz ◽  
Massimo C. Fantini ◽  
Benno Weigmann ◽  
...  

2015 ◽  
Vol 99 (9) ◽  
pp. 1774-1784 ◽  
Author(s):  
Lorenzo Gallon ◽  
Opas Traitanon ◽  
Yuming Yu ◽  
Bo Shi ◽  
Joseph R. Leventhal ◽  
...  

Blood ◽  
2009 ◽  
Vol 114 (12) ◽  
pp. 2417-2426 ◽  
Author(s):  
Carolina Berger ◽  
Michael Berger ◽  
Robert C. Hackman ◽  
Michael Gough ◽  
Carole Elliott ◽  
...  

Abstract The administration of cytokines that modulate endogenous or transferred T-cell immunity could improve current approaches to clinical immunotherapy. Interleukin-2 (IL-2) is used most commonly for this purpose, but causes systemic toxicity and preferentially drives the expansion of CD4+CD25+Foxp3+ regulatory T cells, which can inhibit antitumor immunity. IL-15 belongs to the γc cytokine family and possesses similar properties to IL-2, including the ability to induce T-cell proliferation. Whereas IL-2 promotes apoptosis and limits the survival of CD8+ memory T cells, IL-15 is required for the establishment and maintenance of CD8+ T-cell memory. However, limited data are available to guide the clinical use of IL-15. Here, we demonstrate in nonhuman primates that IL-15 administration expands memory CD8+ and CD4+ T cells, and natural killer (NK) cells in the peripheral blood, with minimal increases in CD4+CD25+Foxp3+ regulatory T cells. Daily administration of IL-15 resulted in persistently elevated plasma IL-15 levels and transient toxicity. Intermittent administration of IL-15 allowed clearance of IL-15 between doses and was safe for more than 3 weeks. These findings demonstrate that IL-15 has profound immunomodulatory properties distinct from those described for IL-2, and suggest that intermittent administration of IL-15 should be considered in clinical studies.


2011 ◽  
Vol 218 (1) ◽  
pp. 53-60 ◽  
Author(s):  
A.C. Foks ◽  
V. Frodermann ◽  
M. ter Borg ◽  
K.L.L. Habets ◽  
I. Bot ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document